Garuda aims to emilimate the dependency on donor or patient cells for blood stem cell transplants.

The company's platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible and transgene-free blood stem cell therapies. Like bone marrow transplants, Garuda’s technology has the potential to address, and possibly cure, more than 120 diseases for a diverse population of patients with unmet medical need.

In February 2023, Garuda announced a $62 million Series B financing, bringing the ​​total amount of funding for the company to $134 million. Proceeds will be used to further advance the development of Garuda’s platform and enable the company to continue the advancement of its proprietary HSC-derived off-the-shelf, durable immune cell program for treating patients with oncologic disorders.